Physician profile
Blake Graham
NPI 1639130180
$933.33
in general payments reported to CMS, 2019-2025
26 companies · $447 in 2025
The $447 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.26 · 2023: $220 · 2024: $255 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $100.93 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Glaxosmithkline, LLC. | $73.20 | 2023-2025 | Bexsero, Rotarix, Pediarix |
| Abbvie INC. | $63.61 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $53.62 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $51.21 | 2023 | Inspire |
| Hologic Sales and Service, LLC | $47.16 | 2024 | Aptima, Thinprep 2000 Processor |
| Edwards Lifesciences Corporation | $46.18 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Electromed, INC. | $44.01 | 2024-2025 | Smartvest |
| Medtronic, INC. | $43.96 | 2025 | Symplicity G3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.23 | 2024-2025 | Caplyta |
| Pfizer INC. | $37.16 | 2024 | |
| Vanda Pharmaceuticals INC. | $34.42 | 2025 | Fanapt |
| Cranial Technologies, INC | $34.23 | 2025 | Doc Band |
| Amgen INC. | $31.10 | 2025 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $25.91 | 2023 | Ajovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $24.28 | 2025 | Zenpep |
| Sanofi Pasteur INC. | $22.35 | 2024 | |
| Abiomed | $21.48 | 2025 | |
| Astellas Pharma US INC | $19.09 | 2024 | Veozah |
| Vertex Pharmaceuticals Incorporated | $19.05 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.99 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $18.78 | 2023 | Fasenra |
| Novo Nordisk INC | $18.22 | 2024 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $15.42 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $14.48 | 2025 | |
| Sobi, INC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.